NCT03681483 - RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG

RO5126766

RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

18103

Lehigh Valley Health Network, Allentown

33143

Miami Cancer Institute, Miami